NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
PhaseV’s Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense’s Phase 3 Trial
CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ — NeuroSense Therapeutics (Nasdaq: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases, today announced that it partnered with PhaseV, a pioneer in causal machine learning (ML) for clinical trial analysis and optimization, with respect to the planned Phase 3 trial of PrimeC as a treatment for amyotrophic lateral sclerosis (ALS).